Effect of selective serotonin reuptake inhibitors on the risk of fracture

Archives of Internal Medicine

Volumn 167, Issue 2, 2007, Pages 188-194

  Richards, J Brent ^a   Papaioannou, Alexandra ^c   Adachi, Jonathan D ^d   Joseph, Lawrence ^a   Whitson, Heather E ^f   Prior, Jerilynn C ^e   Goltzman, David ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE; BISPHOSPHONIC ACID DERIVATIVE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLORAZEPATE DIPOTASSIUM; CLOZAPINE; CORTICOSTEROID; DESIPRAMINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE DECANOATE; FLURAZEPAM; FLUVOXAMINE; HALOPERIDOL; LOXAPINE; LOXAPINE SUCCINATE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENOBARBITAL; PHENYTOIN; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; FALLING; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; VERTEBRA MALFORMATION;

ACCIDENTAL FALLS; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BONE DENSITY; COHORT STUDIES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 33846440508     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.2.188     Document Type: Article

References (59)

1. Ostbye T, Kristjansson B, Hill G, Newman SC, Brouwer RN, McDowell I. Prevalence and predictors of depression in elderly Canadians: the Canadian Study of Health and Aging. Chronic Dis Can. 2005;26:93-99.
2. Schulberg HC, Mulsant B, Schulz R, Rollman BL, Houck PR, Reynolds CF III. Characteristics and course of major depression in older primary care patients. Int J Psychiatry Med. 1998;28:421-436.
3. Oxman TE, Barrett JE, Barrett J, Gerber P. Symptomatology of late-life minor depression among primary care patients. Psychosomatics. 1990;31:174-180.
4. Hayes D. Recent developments in antidepressant therapy in special populations. Am J Manag Care. 2004;10(suppl):S179-S185.
5. Rabheru K. Special issues in the management of depression in older patients. Can J Psychiatry. 2004;49(suppl 1):41S-50S.
6. Emslie G, Judge R. Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr Scand Suppl. 2000;403:26-34.
7. Health. SSRI sales in the United States of America IMS. December 4, 2006. http://www.imshealth.com/ims/portal/front/articleC/0,2777, 6025_4965983_69891394100.html. Accessed November 1, 2006.
8. Health. 2004 Year-end U.S. prescription and sales information and commentary IMS. May 25, 2006. http://www.imshealth.com/ims/portal/front/ articleC/0,2777,6599_3665_69890098,00.html. Accessed October 23, 2006.
9. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303-1307.
10. Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003;158:77-84.
11. Schneeweiss S, Wang PS. Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. J Clin Psychopharmacol. 2004;24:632-638.
12. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17:807-816.
13. French DD, Campbell R, Spehar A, Cunningham F, Foulis P. Outpatient medications and hip fractures in the US: a national veterans study. Drugs Aging. 2005;22:877-885.
14. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003;163:949-957.
15. Warden SJ, Bliziotes MM, Wiren KM, Eshleman AJ, Turner CH. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol. 2005;242:1-9.
16. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29:477-486.
17. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ. Expression of serotonin receptors in bone. J Biol Chem. 2001;276:28961-28968.
18. Battaglino R, Fu J, Spate U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004;19:1420-1431.
19. Bliziotes M, Gunness M, Eshleman A, Wiren K. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact. 2002;2:291-295.
20. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology. 2005;146:685-693.
21. Kreiger N, Tenenhouse A, Joseph L, et al. Research notes: the Canadian Multicentre Osteoporosis Study (CaMos): background, rationale, methods. Can J Aging-Revue Canadienne du Vieillissement. 1999;18:376-387.
22. Lacey CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook . 13th ed. Hudson, Ohio: Lexi-Comp Inc; 2005.
23. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res. 1994;9:1503-1514.
24. Pearson J, Dequeker J, Henley M, et al; European Quantitation of Osteoporosis Study Group. European semi-anthropomorphic spine phantom for the calibration of bone densitometers: assessment of precision, stability and accuracy. Osteoporos Int. 1995;5:174-184.
25. Papaioannou A, Joseph L, Ioannidis G, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int. 2005;16:568-578.
26. Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int. 2000;11:680-687.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
28. Tangalos EG, Smith GE, Ivnik RJ, et al. The Mini-Mental State Examination in general medical practice: clinical utility and acceptance. Mayo Clin Proc. 1996;71:829-837.
29. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA. 1993;269:2386-2391.
30. Ware JE Jr, Snow K, Kowinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, Mass: Health Institute, New England Medical Center; 1993.
31. Beusterien KM, Steinwald B, Ware JE Jr. Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly. J Geriatr Psychiatry Neurol. 1996;9:13-21.
32. Berwick DM, Murphy JM, Goldman PA, Ware JE Jr, Barsky AJ, Weinstein MC. Performance of a five-item mental health screening test. Med Care. 1991;29:169-176.
33. Rogers WH, Adler DA, Bungay KM, Wilson IB. Depression screening instruments made good severity measures in a cross-sectional analysis. J Clin Epidemiol. 2005;58:370-377.
34. Wells KB, Hays RD, Burnam MA, Rogers W, Greenfield S, Ware JE Jr. Detection of depressive disorder for patients receiving prepaid or fee-for-service care: results from the Medical Outcomes Study. JAMA. 1989;262:3298-3302.
35. Ray WA. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med. 1991;151:754-756.
36. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363-369.
37. Ray JG, Papaioannou A, Ioannidis G, Adachi JD. Anticonvulsant drug use and low bone mass in adults with neurodevelopmental disorders. QJM. 2002;95:219-223.
38. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288:321-333.
39. Schoofs MWCJ, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med. 2003;139:476-482.
40. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767-774.
41. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of β-blockers and risk of fractures. JAMA. 2004;292:1326-1332.
42. Baltzan MA, Suissa S, Bauer DC, Cummings SR; Study of Osteoporotic Fractures Group. Hip fractures attributable to corticosteroid use [letter]. Lancet. 1999;353:1327.
43. Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc. 1995;90:773-795.
44. Ihaka R, Gentleman RRR. A language for data analysis and graphics. J Computational Graphical Stat. 1996;5:299-314.
45. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the Study of Osteoporotic Fractures. J Bone Miner Res. 1998;13:1755-1759.
46. Beck CA, Patten SB, Williams JVA, et al. Antidepressant utilization in Canada. Soc Psychiatry Psychiatr Epidemiol. 2005;40:799-807.
47. Paulose-Ram R, Jonas BS, Orwig D, Safran MA. Prescription psychotropic medication use among the U.S. adult population: results from the third National Health and Nutrition Examination Survey, 1988-1994. J Clin Epidemiol. 2004;57:309-317.
48. van Staa TP, Leufkens HGM, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001;16:581-588.
49. + sensitivity. Br J Pharmacol. 1999;127:740-746.
50. + channel opener. Stroke. 1999;30:1949-1954.
51. Cherin P, Colvez A, de Periere GD, Sereni D. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol. 1997;50:313-320.
52. Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ. 1994;150:899-913.
53. Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. JAMA. 1987;257:1492-1495.
54. Kallin K, Gustafson Y, Sandman PO, Karlsson S. Factors associated with falls among older, cognitively impaired people in geriatric care settings: a population-based study. Am J Geriatr Psychiatry. 2005;13:501-509.
55. Melton LJ III, Beard CM, Kokmen E, Atkinson EJ, O'Fallon WM. Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc. 1994;42:614-619.
56. van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-787.
57. van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
58. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-899.
59. Whooley MA, Kip KE, Cauley JA, et al. Depression, falls, and risk of fracture in older women. Arch Intern Med. 1999;159:484-490.